论文部分内容阅读
为探讨生长抑素(SST)Ⅱ型受体激动剂奥曲肽(OCT)和NC-8-12(生长抑素Ⅱ型受体特异激动剂)是否能在体内、体外实验中抑制大肠癌细胞的增殖,采用MTT法对两株大结肠癌细胞株HCT116、LOVO进行不同生长抑素类似物作用下体外细胞增殖状况的研究。并于裸鼠皮下接种大肠癌细胞株HCT116后,皮下给予OCT和NC-8-12治疗,进行体内细胞增值状况的研究。结果发现体外生长实验:10~(-8)mol/L的OCT或NC-8-12作用HCT116、LOVO细胞株24小时后,能明显抑制胰岛素引起的肿瘤细胞增殖作用。治疗HCT116裸鼠移植癌的实验:OCT和 NC-8-12以300μg/(kg·d)的剂量皮下给药共21天的条件下,对肿瘤的生长(以肿瘤的体积和最终瘤重为观察指标)产生显著抑制作用。本文提示生长抑素类似物OCT和NC-8-12在体内、体外实验中均能抑制大肠癌细胞的增殖。
To investigate whether octreotide (OCT), a type II receptor agonist of somatostatin (SST), and NC-8-12 (an agonist of somatostatin type II receptor) can inhibit the proliferation of colorectal cancer cells in vitro and in vivo , MTT assay was used to study the proliferation of two large colon cancer cell lines HCT116 and LOVO under the action of different somatostatin analogues. And inoculated subcutaneously in nude mice colon cancer cell line HCT116, subcutaneous OCT and NC-8-12 treatment for in vivo cell proliferation research. The results showed that the growth of HCT116 and LOVO cells treated with OCT or NC-8-12 at 10 ~ (-8) mol / L for 24 hours could significantly inhibit the proliferation of tumor cells induced by insulin. Treatment of HCT116 transplanted cancer in nude mice: OCT and NC-8-12 were administered subcutaneously for 21 days at a dose of 300 μg / (kg · d) for the growth of the tumor, based on the tumor volume and the final tumor weight Observation index) produced a significant inhibitory effect. This article suggests that somatostatin analogues OCT and NC-8-12 can inhibit the proliferation of colorectal cancer cells in vitro and in vivo.